O. Joe Hines, MD

Oscar (O. Joe) Joe Hines, MD, FACS

Professor and Interim Chair, Department of Surgery
Executive Medical Director, Department of Surgery
Chief, Division of General Surgery
Robert and Kelly Day Chair in General Surgery
Physician, Pancreatic Disease, Esophageal Disorders Center, Department of Medicine, Hematology/Oncology, Pancreatic Cancer Program

Languages

English

Specialty

Surgery General

Education

Internship

Surgery, UCLA School of Medicine, 1990 - 1991

Degree

MD, University of Oklahoma Health Sciences Center, 1990

Residency

Surgery, UCLA School of Medicine, 1991 - 1997

Board Certification

Surgery, American Board of Surgery, 1998, 2006, 2015

Contact Information

Phone

(310) 206-0441 - Office
(310) 794-7788 - Patient Appointments
(310) 825-9427 - Surgery Scheduling

Clinical Interests

Adrenal Glands Cancer, Adrenal Glands Tumor (Benign), Cholecystectomy, Colon Cancer, Colon Tumor (Benign), Fundoplication, Gastrointestinal, General Surgery, Hepatobiliary, Hernia Repair (Epigastric Hernia), Hernia Repair (Femoral Hernia), Hernia Repair (Inguinal Hernia), Hernia Repair (Umbilical Hernia), Ilial-Pouch Anal Anastamosis, Laparoscopic Surgery, Oncology, Pancreatic Cancer, Pancreatic Tumor (Benign), Parathyroid, Parathyroid Tumor (Benign), Rectal Cancer, Rectal Tumor (Benign), Robotics, Stomach Cancer, Stomach Tumor (Benign), Thyroid

Scientific Interests

Dr. Joe Hines studies the role of diet-induced inflammation on pancreatic carcinogenesis.

Highlighted Publications

King JC, Lu QY, Li G, Moro A, Takahashi H, Chen M, Go VL, Reber HA, Eibl G, Hines OJ. Evidence for activation of mutated p53 by apigenin in human pancreatic cancer. Biochim Biophys Acta. 2012 Feb;1823(2):593-604. Epub 2011 Dec 29

Donahue TR, Isacoff WH, Hines OJ, Tomlinson JS, Farrell JJ, Bhat YM, Garon E, Clerkin B, Reber HA. Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery. Arch Surg. 2011 Jul;146(7):836-43.

Li A, King J, Moro A, Sugi MD, Dawson DW, Kaplan J, Li G, Lu X, Strieter RM, Burdick M, Go VL, Reber HA, Eibl G, Hines OJ. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am J Pathol. 2011 Mar;178(3):1340-9.

El Fitori J, Su Y, Buchler P, Ludwig R, Giese NA, Buchler MW, Quentmeier H, Hines OJ, Herr I, Friess H. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer. Cancer. 2007 Oct 1;110(7):1457-68.

Funahashi H, Satake M, Dawson D, Huynh NA, Reber HA, Hines OJ, Eibl G. Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res. 2007 Aug 1;67(15):7068-71. Epub 2007 Jul 24

In the News

View more articles